1
|
Ourry V, Binette AP, St-Onge F, Strikwerda-Brown C, Chagnot A, Poirier J, Breitner J, Arenaza-Urquijo EM, Rabin JS, Buckley R, Gonneaud J, Marchant NL, Villeneuve S. How Do Modifiable Risk Factors Affect Alzheimer's Disease Pathology or Mitigate Its Effect on Clinical Symptom Expression? Biol Psychiatry 2024; 95:1006-1019. [PMID: 37689129 DOI: 10.1016/j.biopsych.2023.09.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/14/2023] [Revised: 08/11/2023] [Accepted: 09/03/2023] [Indexed: 09/11/2023]
Abstract
Epidemiological studies show that modifiable risk factors account for approximately 40% of the population variability in risk of developing dementia, including sporadic Alzheimer's disease (AD). Recent findings suggest that these factors may also modify disease trajectories of people with autosomal-dominant AD. With positron emission tomography imaging, it is now possible to study the disease many years before its clinical onset. Such studies can provide key knowledge regarding pathways for either the prevention of pathology or the postponement of its clinical expression. The former "resistance pathway" suggests that modifiable risk factors could affect amyloid and tau burden decades before the appearance of cognitive impairment. Alternatively, the resilience pathway suggests that modifiable risk factors may mitigate the symptomatic expression of AD pathology on cognition. These pathways are not mutually exclusive and may appear at different disease stages. Here, in a narrative review, we present neuroimaging evidence that supports both pathways in sporadic AD and autosomal-dominant AD. We then propose mechanisms for their protective effect. Among possible mechanisms, we examine neural and vascular mechanisms for the resistance pathway. We also describe brain maintenance and functional compensation as bases for the resilience pathway. Improved mechanistic understanding of both pathways may suggest new interventions.
Collapse
Affiliation(s)
- Valentin Ourry
- Department of Psychiatry, Faculty of Medicine, McGill University, Montreal, Quebec, Canada; Douglas Mental Health University Institute, Montreal, Quebec, Canada.
| | - Alexa Pichet Binette
- Department of Psychiatry, Faculty of Medicine, McGill University, Montreal, Quebec, Canada; Douglas Mental Health University Institute, Montreal, Quebec, Canada; Clinical Memory Research Unit, Department of Clinical Sciences, Lunds Universitet, Malmö, Sweden
| | - Frédéric St-Onge
- Department of Psychiatry, Faculty of Medicine, McGill University, Montreal, Quebec, Canada; Douglas Mental Health University Institute, Montreal, Quebec, Canada; Integrated Program in Neuroscience, Faculty of Medicine, McGill University, Montreal, Quebec, Canada
| | - Cherie Strikwerda-Brown
- Department of Psychiatry, Faculty of Medicine, McGill University, Montreal, Quebec, Canada; Douglas Mental Health University Institute, Montreal, Quebec, Canada; School of Psychological Science, The University of Western Australia, Perth, Western Australia, Australia
| | - Audrey Chagnot
- UK Dementia Research Institute, Edinburgh Medical School, University of Edinburgh, Edinburgh, United Kingdom; Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, United Kingdom
| | - Judes Poirier
- Department of Psychiatry, Faculty of Medicine, McGill University, Montreal, Quebec, Canada; Douglas Mental Health University Institute, Montreal, Quebec, Canada
| | - John Breitner
- Department of Psychiatry, Faculty of Medicine, McGill University, Montreal, Quebec, Canada; Douglas Mental Health University Institute, Montreal, Quebec, Canada
| | - Eider M Arenaza-Urquijo
- Environment and Health over the Lifecourse Programme, Barcelona Institute for Global Health (ISGlobal), Barcelona, Spain; Department of Radiology, Mayo Clinic, Rochester, Minnesota
| | - Jennifer S Rabin
- Division of Neurology, Department of Medicine, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada; Harquail Centre for Neuromodulation, Hurvitz Brain Sciences Program, Sunnybrook Research Institute, University of Toronto, Toronto, Ontario, Canada; Rehabilitation Sciences Institute, University of Toronto, Toronto, Ontario, Canada
| | - Rachel Buckley
- Melbourne School of Psychological Sciences University of Melbourne, Parkville, Victoria, Australia; Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts; Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital, Boston, Massachusetts
| | - Julie Gonneaud
- Normandie University, UNICAEN, INSERM, U1237, PhIND "Physiopathology and Imaging of Neurological Disorders," Institut Blood and Brain @ Caen-Normandie, GIP Cyceron, Caen, France
| | - Natalie L Marchant
- Division of Psychiatry, University College London, London, United Kingdom
| | - Sylvia Villeneuve
- Department of Psychiatry, Faculty of Medicine, McGill University, Montreal, Quebec, Canada; Douglas Mental Health University Institute, Montreal, Quebec, Canada; McConnell Brain Imaging Center, Montreal Neurological Institute, McGill University, Montreal, Quebec, Canada.
| |
Collapse
|
4
|
Demnitz-King H, Gonneaud J, Klimecki OM, Chocat A, Collette F, Dautricourt S, Jessen F, Krolak-Salmon P, Lutz A, Morse RM, Molinuevo JL, Poisnel G, Touron E, Wirth M, Walker Z, Chételat G, Marchant NL. Association of Self-reflection With Cognition and Brain Health in Cognitively Unimpaired Older Adults. Neurology 2022; 99:e1422-e1431. [PMID: 35853750 DOI: 10.1212/wnl.0000000000200951] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/04/2021] [Accepted: 05/24/2022] [Indexed: 02/05/2023] Open
Abstract
BACKGROUND AND OBJECTIVES Self-reflection (the active evaluation of ones thoughts, feelings, and behaviors) can confer protection against adverse health outcomes. Its effect on markers sensitive to Alzheimer disease (AD), however, is unknown. The primary objective of this cross-sectional study was to examine the association between self-reflection and AD-sensitive markers. METHODS This study used baseline data from cognitively unimpaired older adults enrolled in the Age-Well clinical trial and older adults with subjective cognitive decline from the SCD-Well clinical trial. In both cohorts, self-reflection was measured via the reflective pondering subscale of the Rumination Response Scale, global cognition assessed via the Preclinical Alzheimer's Cognitive Composite 5, and a modified late-life Lifestyle-for-Brain-Health (LIBRA) index computed to assess health and lifestyle factors. In Age-Well, glucose metabolism and amyloid deposition were quantified in AD-sensitive gray matter regions via fluorodeoxyglucose- and AV45-PET scans, respectively. Associations between self-reflection and AD-sensitive markers (global cognition, glucose metabolism, and amyloid deposition) were assessed via unadjusted and adjusted regressions. Furthermore, we explored whether associations were independent of health and lifestyle factors. To control for multiple comparisons in Age-Well, false discovery rate-corrected p values (p FDR) are reported. RESULTS A total of 134 (mean age 69.3 ± 3.8 years, 61.9% women) Age-Well and 125 (mean age 72.6 ± 6.9 years, 65.6% women) SCD-Well participants were included. Across unadjusted and adjusted analyses, self-reflection was associated with better global cognition in both cohorts (Age-Well: adjusted-β = 0.22, 95% CI 0.05-0.40, p FDR = 0.041; SCD-Well: adjusted-β = 0.18, 95% CI 0.03-0.33, p = 0.023) and with higher glucose metabolism in Age-Well after adjustment for all covariates (adjusted-β = 0.29, 95% CI 0.03-0.55, p FDR = 0.041). Associations remained following additional adjustment for LIBRA but did not survive false discovery rate (FDR) correction. Self-reflection was not associated with amyloid deposition (adjusted-β = 0.13, 95% CI -0.07 to 0.34, p FDR = 0.189). DISCUSSION Self-reflection was associated with better global cognition in 2 independent cohorts and with higher glucose metabolism after adjustment for covariates. There was weak evidence that relationships were independent from health and lifestyle behaviors. Longitudinal and experimental studies are warranted to elucidate whether self-reflection helps preserve cognition and glucose metabolism or whether reduced capacity to self-reflect is a harbinger of cognitive decline and glucose hypometabolism. TRIAL REGISTRATION INFORMATION Age-Well: NCT02977819; SCD-Well: NCT03005652.
Collapse
Affiliation(s)
- Harriet Demnitz-King
- From the Division of Psychiatry (H.D.-K., R.M.M., Z.W., N.L.M.-A.R.G.), Faculty of Brain Sciences, University College London, United Kingdom; Normandie Univ (J.G., A.C., S.D., G.P., E.T., G.C.), UNICAEN, INSERM, U1237, PhIND "Physiopathology and Imaging Neurological Disorders," Institut Blood and Brain at Caen-Normandie, Cyceron, Caen, France; Clinical Psychology and Behavioural Neuroscience (O.M.K.), Technische Universität Dresden, Germany; GIGA-CRC In Vivo Imaging (F.C.), Université de Liège, Belgium; Department of Psychiatry (F.J.), Medical Faculty, University of Cologne, Germany; Hospices Civils de Lyon (P.K.-S.), Institut du Vielllissement, CRC Vielllissement-Cerveau-Fragilité, France; Lyon Neuroscience Research Center Inserm U1028 (A.L.), CNRS UMR5292, Lyon 1 University, France; Alzheimer's Disease and Other Cognitive Disorders Unit (J.L.M.), Hospital Clinic, IDIBAPS, Barcelona, Spain; and German Center for Neurodegenerative Diseases (DZNE) (M.W.), Dresden
| | - Julie Gonneaud
- From the Division of Psychiatry (H.D.-K., R.M.M., Z.W., N.L.M.-A.R.G.), Faculty of Brain Sciences, University College London, United Kingdom; Normandie Univ (J.G., A.C., S.D., G.P., E.T., G.C.), UNICAEN, INSERM, U1237, PhIND "Physiopathology and Imaging Neurological Disorders," Institut Blood and Brain at Caen-Normandie, Cyceron, Caen, France; Clinical Psychology and Behavioural Neuroscience (O.M.K.), Technische Universität Dresden, Germany; GIGA-CRC In Vivo Imaging (F.C.), Université de Liège, Belgium; Department of Psychiatry (F.J.), Medical Faculty, University of Cologne, Germany; Hospices Civils de Lyon (P.K.-S.), Institut du Vielllissement, CRC Vielllissement-Cerveau-Fragilité, France; Lyon Neuroscience Research Center Inserm U1028 (A.L.), CNRS UMR5292, Lyon 1 University, France; Alzheimer's Disease and Other Cognitive Disorders Unit (J.L.M.), Hospital Clinic, IDIBAPS, Barcelona, Spain; and German Center for Neurodegenerative Diseases (DZNE) (M.W.), Dresden
| | - Olga M Klimecki
- From the Division of Psychiatry (H.D.-K., R.M.M., Z.W., N.L.M.-A.R.G.), Faculty of Brain Sciences, University College London, United Kingdom; Normandie Univ (J.G., A.C., S.D., G.P., E.T., G.C.), UNICAEN, INSERM, U1237, PhIND "Physiopathology and Imaging Neurological Disorders," Institut Blood and Brain at Caen-Normandie, Cyceron, Caen, France; Clinical Psychology and Behavioural Neuroscience (O.M.K.), Technische Universität Dresden, Germany; GIGA-CRC In Vivo Imaging (F.C.), Université de Liège, Belgium; Department of Psychiatry (F.J.), Medical Faculty, University of Cologne, Germany; Hospices Civils de Lyon (P.K.-S.), Institut du Vielllissement, CRC Vielllissement-Cerveau-Fragilité, France; Lyon Neuroscience Research Center Inserm U1028 (A.L.), CNRS UMR5292, Lyon 1 University, France; Alzheimer's Disease and Other Cognitive Disorders Unit (J.L.M.), Hospital Clinic, IDIBAPS, Barcelona, Spain; and German Center for Neurodegenerative Diseases (DZNE) (M.W.), Dresden
| | - Anne Chocat
- From the Division of Psychiatry (H.D.-K., R.M.M., Z.W., N.L.M.-A.R.G.), Faculty of Brain Sciences, University College London, United Kingdom; Normandie Univ (J.G., A.C., S.D., G.P., E.T., G.C.), UNICAEN, INSERM, U1237, PhIND "Physiopathology and Imaging Neurological Disorders," Institut Blood and Brain at Caen-Normandie, Cyceron, Caen, France; Clinical Psychology and Behavioural Neuroscience (O.M.K.), Technische Universität Dresden, Germany; GIGA-CRC In Vivo Imaging (F.C.), Université de Liège, Belgium; Department of Psychiatry (F.J.), Medical Faculty, University of Cologne, Germany; Hospices Civils de Lyon (P.K.-S.), Institut du Vielllissement, CRC Vielllissement-Cerveau-Fragilité, France; Lyon Neuroscience Research Center Inserm U1028 (A.L.), CNRS UMR5292, Lyon 1 University, France; Alzheimer's Disease and Other Cognitive Disorders Unit (J.L.M.), Hospital Clinic, IDIBAPS, Barcelona, Spain; and German Center for Neurodegenerative Diseases (DZNE) (M.W.), Dresden
| | - Fabienne Collette
- From the Division of Psychiatry (H.D.-K., R.M.M., Z.W., N.L.M.-A.R.G.), Faculty of Brain Sciences, University College London, United Kingdom; Normandie Univ (J.G., A.C., S.D., G.P., E.T., G.C.), UNICAEN, INSERM, U1237, PhIND "Physiopathology and Imaging Neurological Disorders," Institut Blood and Brain at Caen-Normandie, Cyceron, Caen, France; Clinical Psychology and Behavioural Neuroscience (O.M.K.), Technische Universität Dresden, Germany; GIGA-CRC In Vivo Imaging (F.C.), Université de Liège, Belgium; Department of Psychiatry (F.J.), Medical Faculty, University of Cologne, Germany; Hospices Civils de Lyon (P.K.-S.), Institut du Vielllissement, CRC Vielllissement-Cerveau-Fragilité, France; Lyon Neuroscience Research Center Inserm U1028 (A.L.), CNRS UMR5292, Lyon 1 University, France; Alzheimer's Disease and Other Cognitive Disorders Unit (J.L.M.), Hospital Clinic, IDIBAPS, Barcelona, Spain; and German Center for Neurodegenerative Diseases (DZNE) (M.W.), Dresden
| | - Sophie Dautricourt
- From the Division of Psychiatry (H.D.-K., R.M.M., Z.W., N.L.M.-A.R.G.), Faculty of Brain Sciences, University College London, United Kingdom; Normandie Univ (J.G., A.C., S.D., G.P., E.T., G.C.), UNICAEN, INSERM, U1237, PhIND "Physiopathology and Imaging Neurological Disorders," Institut Blood and Brain at Caen-Normandie, Cyceron, Caen, France; Clinical Psychology and Behavioural Neuroscience (O.M.K.), Technische Universität Dresden, Germany; GIGA-CRC In Vivo Imaging (F.C.), Université de Liège, Belgium; Department of Psychiatry (F.J.), Medical Faculty, University of Cologne, Germany; Hospices Civils de Lyon (P.K.-S.), Institut du Vielllissement, CRC Vielllissement-Cerveau-Fragilité, France; Lyon Neuroscience Research Center Inserm U1028 (A.L.), CNRS UMR5292, Lyon 1 University, France; Alzheimer's Disease and Other Cognitive Disorders Unit (J.L.M.), Hospital Clinic, IDIBAPS, Barcelona, Spain; and German Center for Neurodegenerative Diseases (DZNE) (M.W.), Dresden
| | - Frank Jessen
- From the Division of Psychiatry (H.D.-K., R.M.M., Z.W., N.L.M.-A.R.G.), Faculty of Brain Sciences, University College London, United Kingdom; Normandie Univ (J.G., A.C., S.D., G.P., E.T., G.C.), UNICAEN, INSERM, U1237, PhIND "Physiopathology and Imaging Neurological Disorders," Institut Blood and Brain at Caen-Normandie, Cyceron, Caen, France; Clinical Psychology and Behavioural Neuroscience (O.M.K.), Technische Universität Dresden, Germany; GIGA-CRC In Vivo Imaging (F.C.), Université de Liège, Belgium; Department of Psychiatry (F.J.), Medical Faculty, University of Cologne, Germany; Hospices Civils de Lyon (P.K.-S.), Institut du Vielllissement, CRC Vielllissement-Cerveau-Fragilité, France; Lyon Neuroscience Research Center Inserm U1028 (A.L.), CNRS UMR5292, Lyon 1 University, France; Alzheimer's Disease and Other Cognitive Disorders Unit (J.L.M.), Hospital Clinic, IDIBAPS, Barcelona, Spain; and German Center for Neurodegenerative Diseases (DZNE) (M.W.), Dresden
| | - Pierre Krolak-Salmon
- From the Division of Psychiatry (H.D.-K., R.M.M., Z.W., N.L.M.-A.R.G.), Faculty of Brain Sciences, University College London, United Kingdom; Normandie Univ (J.G., A.C., S.D., G.P., E.T., G.C.), UNICAEN, INSERM, U1237, PhIND "Physiopathology and Imaging Neurological Disorders," Institut Blood and Brain at Caen-Normandie, Cyceron, Caen, France; Clinical Psychology and Behavioural Neuroscience (O.M.K.), Technische Universität Dresden, Germany; GIGA-CRC In Vivo Imaging (F.C.), Université de Liège, Belgium; Department of Psychiatry (F.J.), Medical Faculty, University of Cologne, Germany; Hospices Civils de Lyon (P.K.-S.), Institut du Vielllissement, CRC Vielllissement-Cerveau-Fragilité, France; Lyon Neuroscience Research Center Inserm U1028 (A.L.), CNRS UMR5292, Lyon 1 University, France; Alzheimer's Disease and Other Cognitive Disorders Unit (J.L.M.), Hospital Clinic, IDIBAPS, Barcelona, Spain; and German Center for Neurodegenerative Diseases (DZNE) (M.W.), Dresden
| | - Antoine Lutz
- From the Division of Psychiatry (H.D.-K., R.M.M., Z.W., N.L.M.-A.R.G.), Faculty of Brain Sciences, University College London, United Kingdom; Normandie Univ (J.G., A.C., S.D., G.P., E.T., G.C.), UNICAEN, INSERM, U1237, PhIND "Physiopathology and Imaging Neurological Disorders," Institut Blood and Brain at Caen-Normandie, Cyceron, Caen, France; Clinical Psychology and Behavioural Neuroscience (O.M.K.), Technische Universität Dresden, Germany; GIGA-CRC In Vivo Imaging (F.C.), Université de Liège, Belgium; Department of Psychiatry (F.J.), Medical Faculty, University of Cologne, Germany; Hospices Civils de Lyon (P.K.-S.), Institut du Vielllissement, CRC Vielllissement-Cerveau-Fragilité, France; Lyon Neuroscience Research Center Inserm U1028 (A.L.), CNRS UMR5292, Lyon 1 University, France; Alzheimer's Disease and Other Cognitive Disorders Unit (J.L.M.), Hospital Clinic, IDIBAPS, Barcelona, Spain; and German Center for Neurodegenerative Diseases (DZNE) (M.W.), Dresden
| | - Rachel M Morse
- From the Division of Psychiatry (H.D.-K., R.M.M., Z.W., N.L.M.-A.R.G.), Faculty of Brain Sciences, University College London, United Kingdom; Normandie Univ (J.G., A.C., S.D., G.P., E.T., G.C.), UNICAEN, INSERM, U1237, PhIND "Physiopathology and Imaging Neurological Disorders," Institut Blood and Brain at Caen-Normandie, Cyceron, Caen, France; Clinical Psychology and Behavioural Neuroscience (O.M.K.), Technische Universität Dresden, Germany; GIGA-CRC In Vivo Imaging (F.C.), Université de Liège, Belgium; Department of Psychiatry (F.J.), Medical Faculty, University of Cologne, Germany; Hospices Civils de Lyon (P.K.-S.), Institut du Vielllissement, CRC Vielllissement-Cerveau-Fragilité, France; Lyon Neuroscience Research Center Inserm U1028 (A.L.), CNRS UMR5292, Lyon 1 University, France; Alzheimer's Disease and Other Cognitive Disorders Unit (J.L.M.), Hospital Clinic, IDIBAPS, Barcelona, Spain; and German Center for Neurodegenerative Diseases (DZNE) (M.W.), Dresden
| | - José Luis Molinuevo
- From the Division of Psychiatry (H.D.-K., R.M.M., Z.W., N.L.M.-A.R.G.), Faculty of Brain Sciences, University College London, United Kingdom; Normandie Univ (J.G., A.C., S.D., G.P., E.T., G.C.), UNICAEN, INSERM, U1237, PhIND "Physiopathology and Imaging Neurological Disorders," Institut Blood and Brain at Caen-Normandie, Cyceron, Caen, France; Clinical Psychology and Behavioural Neuroscience (O.M.K.), Technische Universität Dresden, Germany; GIGA-CRC In Vivo Imaging (F.C.), Université de Liège, Belgium; Department of Psychiatry (F.J.), Medical Faculty, University of Cologne, Germany; Hospices Civils de Lyon (P.K.-S.), Institut du Vielllissement, CRC Vielllissement-Cerveau-Fragilité, France; Lyon Neuroscience Research Center Inserm U1028 (A.L.), CNRS UMR5292, Lyon 1 University, France; Alzheimer's Disease and Other Cognitive Disorders Unit (J.L.M.), Hospital Clinic, IDIBAPS, Barcelona, Spain; and German Center for Neurodegenerative Diseases (DZNE) (M.W.), Dresden
| | - Géraldine Poisnel
- From the Division of Psychiatry (H.D.-K., R.M.M., Z.W., N.L.M.-A.R.G.), Faculty of Brain Sciences, University College London, United Kingdom; Normandie Univ (J.G., A.C., S.D., G.P., E.T., G.C.), UNICAEN, INSERM, U1237, PhIND "Physiopathology and Imaging Neurological Disorders," Institut Blood and Brain at Caen-Normandie, Cyceron, Caen, France; Clinical Psychology and Behavioural Neuroscience (O.M.K.), Technische Universität Dresden, Germany; GIGA-CRC In Vivo Imaging (F.C.), Université de Liège, Belgium; Department of Psychiatry (F.J.), Medical Faculty, University of Cologne, Germany; Hospices Civils de Lyon (P.K.-S.), Institut du Vielllissement, CRC Vielllissement-Cerveau-Fragilité, France; Lyon Neuroscience Research Center Inserm U1028 (A.L.), CNRS UMR5292, Lyon 1 University, France; Alzheimer's Disease and Other Cognitive Disorders Unit (J.L.M.), Hospital Clinic, IDIBAPS, Barcelona, Spain; and German Center for Neurodegenerative Diseases (DZNE) (M.W.), Dresden
| | - Edelweiss Touron
- From the Division of Psychiatry (H.D.-K., R.M.M., Z.W., N.L.M.-A.R.G.), Faculty of Brain Sciences, University College London, United Kingdom; Normandie Univ (J.G., A.C., S.D., G.P., E.T., G.C.), UNICAEN, INSERM, U1237, PhIND "Physiopathology and Imaging Neurological Disorders," Institut Blood and Brain at Caen-Normandie, Cyceron, Caen, France; Clinical Psychology and Behavioural Neuroscience (O.M.K.), Technische Universität Dresden, Germany; GIGA-CRC In Vivo Imaging (F.C.), Université de Liège, Belgium; Department of Psychiatry (F.J.), Medical Faculty, University of Cologne, Germany; Hospices Civils de Lyon (P.K.-S.), Institut du Vielllissement, CRC Vielllissement-Cerveau-Fragilité, France; Lyon Neuroscience Research Center Inserm U1028 (A.L.), CNRS UMR5292, Lyon 1 University, France; Alzheimer's Disease and Other Cognitive Disorders Unit (J.L.M.), Hospital Clinic, IDIBAPS, Barcelona, Spain; and German Center for Neurodegenerative Diseases (DZNE) (M.W.), Dresden
| | - Miranka Wirth
- From the Division of Psychiatry (H.D.-K., R.M.M., Z.W., N.L.M.-A.R.G.), Faculty of Brain Sciences, University College London, United Kingdom; Normandie Univ (J.G., A.C., S.D., G.P., E.T., G.C.), UNICAEN, INSERM, U1237, PhIND "Physiopathology and Imaging Neurological Disorders," Institut Blood and Brain at Caen-Normandie, Cyceron, Caen, France; Clinical Psychology and Behavioural Neuroscience (O.M.K.), Technische Universität Dresden, Germany; GIGA-CRC In Vivo Imaging (F.C.), Université de Liège, Belgium; Department of Psychiatry (F.J.), Medical Faculty, University of Cologne, Germany; Hospices Civils de Lyon (P.K.-S.), Institut du Vielllissement, CRC Vielllissement-Cerveau-Fragilité, France; Lyon Neuroscience Research Center Inserm U1028 (A.L.), CNRS UMR5292, Lyon 1 University, France; Alzheimer's Disease and Other Cognitive Disorders Unit (J.L.M.), Hospital Clinic, IDIBAPS, Barcelona, Spain; and German Center for Neurodegenerative Diseases (DZNE) (M.W.), Dresden
| | - Zuzana Walker
- From the Division of Psychiatry (H.D.-K., R.M.M., Z.W., N.L.M.-A.R.G.), Faculty of Brain Sciences, University College London, United Kingdom; Normandie Univ (J.G., A.C., S.D., G.P., E.T., G.C.), UNICAEN, INSERM, U1237, PhIND "Physiopathology and Imaging Neurological Disorders," Institut Blood and Brain at Caen-Normandie, Cyceron, Caen, France; Clinical Psychology and Behavioural Neuroscience (O.M.K.), Technische Universität Dresden, Germany; GIGA-CRC In Vivo Imaging (F.C.), Université de Liège, Belgium; Department of Psychiatry (F.J.), Medical Faculty, University of Cologne, Germany; Hospices Civils de Lyon (P.K.-S.), Institut du Vielllissement, CRC Vielllissement-Cerveau-Fragilité, France; Lyon Neuroscience Research Center Inserm U1028 (A.L.), CNRS UMR5292, Lyon 1 University, France; Alzheimer's Disease and Other Cognitive Disorders Unit (J.L.M.), Hospital Clinic, IDIBAPS, Barcelona, Spain; and German Center for Neurodegenerative Diseases (DZNE) (M.W.), Dresden
| | - Gaël Chételat
- From the Division of Psychiatry (H.D.-K., R.M.M., Z.W., N.L.M.-A.R.G.), Faculty of Brain Sciences, University College London, United Kingdom; Normandie Univ (J.G., A.C., S.D., G.P., E.T., G.C.), UNICAEN, INSERM, U1237, PhIND "Physiopathology and Imaging Neurological Disorders," Institut Blood and Brain at Caen-Normandie, Cyceron, Caen, France; Clinical Psychology and Behavioural Neuroscience (O.M.K.), Technische Universität Dresden, Germany; GIGA-CRC In Vivo Imaging (F.C.), Université de Liège, Belgium; Department of Psychiatry (F.J.), Medical Faculty, University of Cologne, Germany; Hospices Civils de Lyon (P.K.-S.), Institut du Vielllissement, CRC Vielllissement-Cerveau-Fragilité, France; Lyon Neuroscience Research Center Inserm U1028 (A.L.), CNRS UMR5292, Lyon 1 University, France; Alzheimer's Disease and Other Cognitive Disorders Unit (J.L.M.), Hospital Clinic, IDIBAPS, Barcelona, Spain; and German Center for Neurodegenerative Diseases (DZNE) (M.W.), Dresden
| | - Natalie L Marchant
- From the Division of Psychiatry (H.D.-K., R.M.M., Z.W., N.L.M.-A.R.G.), Faculty of Brain Sciences, University College London, United Kingdom; Normandie Univ (J.G., A.C., S.D., G.P., E.T., G.C.), UNICAEN, INSERM, U1237, PhIND "Physiopathology and Imaging Neurological Disorders," Institut Blood and Brain at Caen-Normandie, Cyceron, Caen, France; Clinical Psychology and Behavioural Neuroscience (O.M.K.), Technische Universität Dresden, Germany; GIGA-CRC In Vivo Imaging (F.C.), Université de Liège, Belgium; Department of Psychiatry (F.J.), Medical Faculty, University of Cologne, Germany; Hospices Civils de Lyon (P.K.-S.), Institut du Vielllissement, CRC Vielllissement-Cerveau-Fragilité, France; Lyon Neuroscience Research Center Inserm U1028 (A.L.), CNRS UMR5292, Lyon 1 University, France; Alzheimer's Disease and Other Cognitive Disorders Unit (J.L.M.), Hospital Clinic, IDIBAPS, Barcelona, Spain; and German Center for Neurodegenerative Diseases (DZNE) (M.W.), Dresden.
| | | |
Collapse
|